RUNX2 and osteosarcoma: We previously found that the RUNX2/p53 complex is recruited onto p53 target promoters in osteosarcoma U2OS cells treated with ADR, leading to inhibition of the DNA-damage-induced transcriptional activity and pro-apoptotic activity of p53 [69] (Figure 3B).